Progress and challenges in therapies for AIDS in nonhuman primate models

Journal of Medical Primatology

Volumn 28, Issue 4-5, 1999, Pages 154-163

  Haigwood, Nancy L ^a  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antibodies; Antiviral drugs; HIVIG; IgG; Passive immunotherapy; SIVIG

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G;

ANIMAL; DISEASE COURSE; DISEASE MODEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MONKEY DISEASE; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PRIMATE; REVIEW; TIME;

AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; PRIMATES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TIME FACTORS;

EID: 0033175405     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0684.1999.tb00264.x     Document Type: Article

References (57)

1. A Global Disaster. Economist 350:42, issue 2, Jan 1999.
2. AGY MB, FRUMKIN LR, COREY L, COOMBS RW, WOLINSKY SM, KOEHLER J, MORTON WR, KATZE MG: Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science 257:103-106, 1992.
3. BARNETT SW, MURTHY KK, HERNDIER BG, LEVY JA: An AIDS-like condition induced in baboons by HIV-2. Science 266:642-646, 1994.
4. CASTRO BA, NEPOMUCENO M, LERCHE NW, EICHBERG JW, LEVY JA: Perisistent infection of baboons and rhesus monkeys with different strains of HIV-2. Virology 184:219-226, 1991.
5. CONLEY AJ, KESSLER JAI, BOOTS LJ, MCKENNA PM, SCHLEIF WA, EMINI EA, MARK GEI, KATINGER H, COBB EK, LUNCEFORD SM, ROUSE SR, MURTHY KK: The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary isolate. J Virol 70:6751-6758, 1996.
6. DESROSIERS RC, RINGLER DJ: Use of simian immunodeficiency viruses for AIDS research. Intervirology 30:301-312, 1989.
7. EMINI EA, SCHLEIF WA, NUNBERG JH, CONLEY AJ, EDA Y, TOKIYOSHI S, PUTNEY SD, MATSUSHITA S, COBB KE, JETT CM, EICHBERG JW, MURTHY KK: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730, 1992.
8. FORESMAN L, JIA F, LI Z, WANG C, STEPHENS EB, SAHNI M, NARAYAN O, JOAG SV: Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res Hum Retro 14:1035-1043, 1998.
9. FULTZ PN, SCHWIEBERT R, STALLWORTH J: AIDS-like disease following mucosal infection of pig-tailed macaques with SIVsmmPBj 14. J Med Primatol 24:102-107, 1995.
10. GAO F, ROBERTSON DL, CARRUTHERS CD, LI Y, BAILES E, KOSTRIKIS LG, SALMINEN MO, BIBOLLET-RUCHE F, PEETERS M, HO DD, SHAW GM, SHARP PM, HAHN BH: Origin of HIV-I in the chimpanzee Pan troglodytes troglodytes. Nature 397:436-441, 1999.
11. GAUDUIN M-C, PARREN PWHI, WEIR R, BARBAS CFI, BURTON DR, KOUP RA: Passive immunization with a potent neutralizing human monoclonal antibody protects HU-PBL-SCID mice against challenge by primary isolates of human immunodeficiency virus type 1. Nat Med 3:1389-1393, 1997.
12. HAIGWOOD NL, WATSON A, SUTTON WF, MCCLURE J, LEWIS A, RANCHALIS J, TRAVIS B, Voss G, LETVIN NL, Hu S-L, HIRSCH VM, JOHNSON PR: Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile. Imm Lett 51:107-114, 1996.
13. HAROUSE JM, TAN RCH, GETTIE A, DAILEY P, MARX PA, LUCIW PA, CHENG-MAYER C: Mucosal transmission of pathogenic CXCR4-utilizing SHIV SF33A variants in rhesus macaques. Virology 248:95-107, 1998.
14. HENDERSON DK: Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA 281:931, 1999.
15. HIOE CE, XU S, CHIGURUPATI P, BURDA S, WILLIAMS C, CORNY MK, ZOLLA-PAZNER S: Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immuno 9:1281-1290, 1997.
16. HO DD: Toward HIV eradication or remisssion: The tasks ahead. Science 280:1866-1867, 1998.
17. HU S-L, HAIGWOOD NL, MORTON WR: Non-human primate models for AIDS research. In: Morrow WJW, Haigwood NL (eds). HIV Molecular Organization, Pathogenicity and Treatment. Elsevier Science Publishers: Amsterdam 293-327, 1993.
18. IGARASHI T, BROWN C, AZADEGAN A, HAIGWOOD N, DIMITROV D, MARTIN MA, SHIBATA R: Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 5:211-216, 1999.
19. IGARASHI T, SHIBATA R, HASEBE F, AMI Y, SHINOHARA K, KOMATSU T, STAHL-HENNING C, PETRY H, HUNSMANN G, KUWATA T, JIN M, ADACHI A, KURIMURA T, OKADA M, MIURA T, HAYAMI M: Persistent infection of SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys. AIDS Res Hum Retrov 10:1021-1029, 1994.
20. JOAG SV, LI Z, FORESMAN L, PINSON DM, RAGHAVAN R, ZHUGE W, ADANY I, WANG C, JIA F, SHEFFER D, RANCHALIS J, WATSON A, NARAYAN O: Characterization of the pathogenic KUSHIV model of acquired immunodeficiency syndrome in macaques. AIDS Res Hum Retrovir 13:635-645, 1997.
21. JOAG SV, LI Z, FORESMAN L, PINSON DM, STEPHENS EB, RAGHAVAN R, NAVE J-F, CASARA P, NARAYAN O: Early treatment with 9-(2-phosphonylmehoxyethyl)adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques. AIDS Res Hum Retrovir 13:241-246, 1997.
22. JOAG SV, LI Z, FORESMAN L, STEPHENS EB, ZHAO LJ, ADANY I, PINSON DM, MCCLURFE HM, NARAYAN O: Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol 70:3189-3197, 1996.
23. KINLOCH-DELOES S, HIRSCHEL BJ, HOEN B, COOPER DA, TINDALL B, CARR A, SAURAT J-H, CLUMECK N, LAZZARIN A, MATHIESEN L, RAFFI F, ANTUNES F, VON OVERBECK J, LÜTHY R, GLAUSER M, HAWKINS D, BAUMBERGER C, YERLY S, PERNEGER TV, PERRIN L: A controlled trial of zidovudine in primary human immunodeficiency virus infection. NE J Med 333:450-451, 1995.
24. LEWIS MG, ELKINS WR, MCCUTCHAN FE, BENVENISTE RE, LAI CY, MONTEFIORI DC, BURKE DS, EDDY GA, SHAFFERMAN A: Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 11:1347-1355, 1993.
25. LI A, KATINGER H, POSNER MR, CAVACINI L, ZOLLA-PAZNER S, CORNY MK, SODROSKI J, CHOU T-C, BABA TW, RUPRECHT RM: Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu + by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol 72:3235-3240, 1998.
26. LI J, LORD CI, HASELTINE W, LETVIN NL, SODROSKI J: Infection of cynomolgus monkeys with a chimeric HIV-1/ SIVmac virus that expresses the HIV-1 envelope glycoproteins. J AIDS 5:639-646, 1992.
27. LIFSON JD, NOWAK MA, GOLDSTEIN S, ROSSIO JL, KINTER A, VASQUEZ G, WILTROUT TA, BROWN C, SCHNEIDER D, WAHL L, LLOYD AL, WILLIAMS J, ELKINS WR, FAUCI AS, HIRSCH VM: The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 71:9508-9514, 1997.
28. LOHMAN BL, MCCHESNEY MB, MILLER CJ, MCGOWAN E, JOYE SM, VAN ROMPAY KKA, REAY E, ANTIPA L, PEDERSEN NC, MARTHAS ML: A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 68:7021-7029, 1994.
29. MARTHAS ML, SUTJIPTO L, MILLER CJ, HIGGINS J, TORTEN J, LOHMAN B, UNGER R, MARX P, PEDERSON N, KIYONO H, MCGEE J: Immunization with live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol 64:3694-3700, 1990.
30. MARTIN LN, MURPHEY-CORB M, MACK P, BASKIN GB, PANTALEO G, VACCAREZZA M, Fox CH, FAUCI AS: Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys. J Infect Dis 176:374-383, 1997.
31. MARTIN LN, MURPHEY-CORB M, SOIKE KF, DAVISON-FAIRBURN B, BASKIN GB: Effects of initiation of 3′-azido,3′-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 168:825-835, 1993.
32. MARTIN LN, SOIKE KF, MURPHEY-CORB M, BOHM RP, ROBERTS ED, KAKUK TJ, THAISRIBONGS S, VIDMAR TJ, RUWART MJ, DAVIO SR: Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. Antimicrob Agents Chemother 38:1277-1283, 1994.
33. MILLER C, GARDNER MB: AIDS and mucosal immunity-usefulness of the SIV macaque model of genital mucosal transmission. J Acq Imm Def Syndromes 4:1169-1172, 1991.
34. MURPHEY-CORB M, MONTELARO RC, MILLER MA, WEST M, MARTIN LN, DAVISON-FAIRBURN B, OHKAWA S, BASKIN GB, ZHANG J-Y, MILLER GB, PUTNEY SD, ALLISON AC, EPPSTEIN DA: Efficacy of SIV/DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. AIDS 5:655-662, 1991.
35. NOVEMBRE GJ, SAUCIER M, ANDERSON DC, KLUMPP SA, O'NEIL SP, BROWN CRI, HART CE, GUENTHNER PC, SWENSON RB, MCCLURE HM: Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. Virol 71:4086-4091, 1997.
36. PRINCE AM, REESINK H, PASCUAL D, HOROWITZ B, HEWLETT I, MURTHY KK, COBB KE, EICHBERG J: Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retrov 7:971-973, 1991.
37. PRINCE M, HOROWITZ B, BAKER L, SHULMAN R, RALPH H, VALINSKY J, CUNDELL A, BROTMAN B, BOEHLE W, REY F, PIET M, REESINK H, LELIE N, TERSMETTE M, MIEDEMA F, BARBOSA L, NEMO G, NASTALA C, ALLAN J, LEE R, EICHBERG J: Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci (USA) 85:6944-6948, 1988.
38. REIMANN KA, LI JT, VEAZEY R, HALLORAN M, PARK IW, KARLSSON GB, SODROSKI J, LETVIN NL: A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 70:6922-6928, 1996.
39. SHIBATA R, IGARASHI T, HAIGWOOD N, BUCKLER-WHITE A, OGERT R, ROSS W, WILLEY R, CHO MW, MARTIN MA: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/ SIV chimeric virus infections of macaque monkeys. Nat Med 5:204-210, 1999.
40. SHIBATA R, MALDARELLI F, SIEMON C, MATANO T, PARTA M, MILLER G, FREDERICKSON T, MARTIN MA: Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing. J Infect Dis 176:362-373, 1997.
41. SPIRA AI, MARX PA, PATTERSON BK, MAHONEY J, KOUP RA, WOLINSKY SM, HO DD: Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183:215-225, 1996.
42. TSAI C-C, EMAU P, FOLLIS KE, BECK TW, BENVENISTE RE, BISCHOFBERGER N, LIFSON JD, MORTON WR: Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 72:4265-4273, 1998.
43. TSAI C-C, FOLLIS KE, BECK TW, SABO A, BISCHOFBERGER N, DAILEY PJ: Effects of (R)-9-(2phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retrovir 13:707-712, 1997.
44. TSAI C-C, FOLLIS KE, GRANT R, SABO A, NOLTE R, BARTZ C, BISCHOFBERGER N, BENVENISTE R: Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques. J Med Primatol 23:175-183, 1994.
45. TSAI C-C, FOLLIS KE, SABO A, BECK TW, GRANT RF, BISCHOFBERGER N, BENVENISTE RE, BLACK R: Prevention of SIV infection in macaques by (R)-9-(2phosphonylmethoxypropyl)adenine. Science 270:1197-1199, 1995.
46. TSAI C-C, FOLLIS KE, SABO A, BECK TW, GRANT RF, BISCHOFBERGER N, BENVENISTE RE, BLACK R: Prevention of SIV infection in macaques by (R)-9-(2phosphonylmethoxypropyl)adenine. Science 270:1197-1199, 1995.
47. VAN ROMPAY KKA, BERARDI CJ, AGUIRRE NL, BISCHOFBERGER N, LIETMAN PS, PEDERSON NC, MARTHAS ML: Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 12:F79-F83, 1998.
48. VAN ROMPAY KKA, BERARDI CJ, DILLARD-TELM S, TARARA RP, CANFIELD DR, VALVERDE CR, MONTELARO RC, MILLER CJ, MARTHAS ML: Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 177:1247-1259, 1998.
49. VAN ROMPAY KKA, CHERRINGTON JM, MARTHAS ML, BERARDI CJ, MULATO AS, SPINNER A, TARARA RP, CANFIELD DR, TELM S, BISCHOFBERGER N, PEDERSEN NC: 9-[2(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 40:2586-2591, 1996.
50. VAN ROMPAY KKA. DAILEY PJ, TARARA RP, CANFIELD DR, AGUIRRE NL, CHERRINGTON JM, BISCHOFBERGER N, PEDERSEN NC, MARTHAS ML: Early short-term 9-[2(phosphonomethoxy)proply]adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 73:2947-2955, 1999.
51. VAN ROMPAY KKA, MARTHAS ML, LIFSON JD, BERARDI CJ, VASQUEZ GM, AGATEP E, DEHQANZADA ZA, CUNDY KC, BISCHOFBERGER N, PEDERSON NC: Administration of 9-[2(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retrovir 14:761-773, 1998.
52. VAN ROMPAY KKA, OTSYULA MG, MARTHAS ML, MILLER CJ, MCCHESNEY MB, PEDERSEN NC: Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 39:125-131, 1995.
53. VITTECOQ D, CHEVRET S, MORAND-JOUBERT L, HESHMATI F, AUDAT F, BARY M. DUSAUTOIR T, BISMUTH A, VIARD JP, BARRE-SINOUSSI F, BACH JF, LEFRERE JJ: Passive immunotherapy in AIDS: A double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 92:1195-1199, 1995.
54. VITTECOQ D, MATTLINGER B, BARRE-SINOUSSI F, COUROUCE AM, ROUZIOUX C, DOINEL C, BARY M, VIARD JP, BACH JF, ROUGER P, LEFRERE JJ: Passive immunotherapy in AIDS: A randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis 165:364-368, 1992.
55. WATSON A, MCCLURE J, RANCHALIS J, SCHEIBEL M, SCHMIDT A, KENNEDY B, MORTON WR, HAIGWOOD NL, Hu S-L: Early postinfection antiviral treatment reduces viral load and prevents CD4 + cell decline in HIV type 2-infected macaques. AIDS Res Hum Retrov 13:1375-1381, 1997.
56. WATSON A, RANCHALIS J, TRAVIS B, MCCLURE J, SUTTON W, JOHNSON PR, Hu S-L, HAIGWOOD NL: Plasma viremia in macaques infected with SIV: Plasma virus load early in infection predicts survival. J Virol 71:284-290, 1997.
57. WYAND MS: The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. AIDS Res Hum Retro 8:349-356, 1992.